Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MURRAY A SNOOK

Allopathic & Osteopathic Physicians Family Medicine

NPI
1326125097
CMS profile
15473
Location
LEANDER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,315.32

178 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,315.32 178

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MURRAY A SNOOK

NPI 1326125097 · CMS profile ID 15473

Allopathic & Osteopathic Physicians / Family Medicine

LEANDER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326125097?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MURRAY A SNOOK, NPI 1326125097, CMS profile ID 15473. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326125097?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MURRAY A SNOOK, NPI 1326125097, CMS profile ID 15473. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326125097?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MURRAY A SNOOK, NPI 1326125097, CMS profile ID 15473, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1326125097?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

178 matching records · $3,315.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 178 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 178.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $18.4209/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020645925 CMS
Lilly USA, LLC $63.8909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032089883 CMS
Otsuka America Pharmaceutical, Inc. $22.5009/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014833389 CMS
Lilly USA, LLC $63.9009/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031922507 CMS
Lilly USA, LLC $1.7809/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032038487 CMS
PFIZER INC. $2.9909/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050506587 CMS
Novo Nordisk Inc $11.5509/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001116741 CMS
AbbVie Inc. $22.1009/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999058519 CMS
Abbott Laboratories $141.2309/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019395123 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0009/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997006419 CMS
Corium, LLC $24.3309/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978298307 CMS
Dexcom, Inc. $15.6209/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054945635 CMS
Boston Scientific Corporation $101.5009/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022545335 CMS
Novo Nordisk Inc $19.6909/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001116823 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.6109/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057268263 CMS
Tris Pharma Inc $22.7309/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059344263 CMS
AstraZeneca Pharmaceuticals LP $16.2808/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011929861 CMS
Lilly USA, LLC $11.6808/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032089887 CMS
Lilly USA, LLC $16.1508/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032112983 CMS
AbbVie Inc. $3.5008/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999058517 CMS
Amgen Inc. $17.3908/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020645923 CMS
Janssen Pharmaceuticals, Inc $26.2208/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987975089 CMS
Ironshore Pharmaceuticals Inc. $14.9608/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060506135 CMS
Abbott Laboratories $1.5408/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018712445 CMS
PFIZER INC. $24.8208/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049604717 CMS
Abbott Laboratories $1.5408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018710689 CMS
Abbott Laboratories $1.5408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018710811 CMS
GlaxoSmithKline, LLC. $1.9308/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001666907 CMS
GlaxoSmithKline, LLC. $3.8208/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001667313 CMS
Otsuka America Pharmaceutical, Inc. $17.8608/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014833379 CMS
Novo Nordisk Inc $23.5108/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001116857 CMS
PFIZER INC. $25.4308/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049268015 CMS
Lilly USA, LLC $12.3608/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032038493 CMS
Exact Sciences Corporation $13.1408/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026507281 CMS
Janssen Pharmaceuticals, Inc $20.5308/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987975097 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $16.3708/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057334683 CMS
PFIZER INC. $1.8708/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049530327 CMS
PFIZER INC. $10.2108/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050436285 CMS
AbbVie Inc. $27.3407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999058515 CMS
Amgen Inc. $17.5807/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020645921 CMS
Lilly USA, LLC $14.4607/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032038497 CMS
AstraZeneca Pharmaceuticals LP $14.2607/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011697127 CMS
Ironshore Pharmaceuticals Inc. $14.9507/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060506339 CMS
Otsuka America Pharmaceutical, Inc. $21.0107/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014833369 CMS
Corium, LLC $20.8007/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978467775 CMS
Exact Sciences Corporation $23.8007/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026507275 CMS
Astellas Pharma US Inc $17.8907/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034257383 CMS
GlaxoSmithKline, LLC. $16.1107/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001667333 CMS
AstraZeneca Pharmaceuticals LP $14.9807/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011251257 CMS
GlaxoSmithKline, LLC. $24.6207/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001666305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,827.69 251
PY2020 $4,736.35 262
PY2021 $4,761.79 221
PY2022 $2,990.61 158
PY2023 $3,315.32 178
PY2024 $4,819.15 179
PY2025 $3,278.34 157

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $161,261.80 25
PY2024 Recipient $1,569.51 9
PY2024 Principal investigator $113,583.35 12
PY2023 Principal investigator $35,419.31 6
PY2022 Principal investigator $184,469.97 19
PY2021 Principal investigator $386,420.69 48
PY2020 Principal investigator $199,985.76 29
PY2019 Principal investigator $23,160.36 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,237.40 12/11/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184274522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,118.70 12/04/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184269085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,118.70 11/20/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184263609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,138.10 11/07/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184258869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,508.40 10/16/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184250901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,237.40 09/23/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184241752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,494.20 09/12/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184236680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,511.00 07/17/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184216972
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,237.40 07/04/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184212713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,118.70 06/19/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184209085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,237.40 06/05/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184204105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $989.10 05/28/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184198829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,118.70 05/22/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184197541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,399.60 05/22/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184197543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,254.20 05/15/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184194603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $838.80 05/08/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184193721
Principal investigator 1 Acella Pharmaceuticals, LLC $66,398.00 05/02/2025 Non-covered Recipient Entity
Advanced Medical Trials Georgetown, LLC
RANDOMIZED, BLINDED, 4-WAY CROSSOVER STUDY TO DETERMINE THE DOSAGE FORM PROPORTIONALITY, SAFETY, AND TOLERABILITY OF 3 DOSAGE FORMS OF NORTH STAR DESICCATED PORCINE THYROID EXTRACT TABLETS IN HEALTHY SUBJECTS No dispute reported 06/30/2026 1241766008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,160.20 04/28/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184190789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,627.10 04/15/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184183438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,090.70 04/01/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184180870
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,118.70 03/19/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184174604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,209.40 03/11/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184170908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,957.50 02/25/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184155386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,490.60 02/11/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184152942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,651.80 02/05/2025 Non-covered Recipient Entity
ADVANCED MEDICAL TRIALS GEORGETOWN LLC
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors No dispute reported 06/30/2026 1184152428